A Varegacestat Hepatic Impairment Study
NCT06841315 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2026-03-10
Summary
This clinical trial is designed to determine the pharmacokinetics, safety and tolerability of varegacestat in people with impaired liver function compared to people with normal liver function.
Conditions
- Healthy Volunteer
- Hepatic Impairment (HI)
Interventions
- DRUG
-
varegacestat
experimental intervention
Sponsors & Collaborators
-
Immunome, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 84 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-03-07
- Primary Completion
- 2025-11-05
- Completion
- 2026-03-06
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
NCT06908954 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects
NCT02135302 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect of Mild and Moderate Hepatic Impairment on the Safety and Tolerability of Fezolinetant Compared to Participants With Normal Hepatic Function
NCT04482270 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function
NCT04116476 ·Status: COMPLETED ·Phase: PHASE1
-
MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function
NCT02050815 ·Status: TERMINATED ·Phase: PHASE1
-
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
NCT05610657 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib
NCT04772612 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780
NCT06576765 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
NCT05684653 ·Status: UNKNOWN ·Phase: PHASE1
-
Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment
NCT01594957 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
NCT05440344 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate Severe Hepatic Impairment on Dacomitinib PK
NCT03865446 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)
NCT01465412 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
NCT05624710 ·Status: COMPLETED ·Phase: PHASE1
-
A PK and Safety Study in Subjects With Hepatic Impairment
NCT01431833 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
NCT04223635 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
NCT04639115 ·Status: COMPLETED ·Phase: PHASE1
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
NCT06952634 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001
NCT06619054 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects
NCT01405599 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment
NCT03423446 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
NCT02170571 ·Status: COMPLETED ·Phase: PHASE1
-
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
NCT02121860 ·Status: COMPLETED ·Phase: PHASE1
-
A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment
NCT04225936 ·Status: COMPLETED ·Phase: PHASE1
-
Tepotinib Hepatic Impairment Trial
NCT03546608 ·Status: COMPLETED ·Phase: PHASE1